Cargando…
Tofacitinib Associated with Reduced Intubation Rates in the Management of Severe COVID-19 Pneumonia: A Preliminary Experience
BACKGROUND: The second wave of COVID-19 pandemic was not only associated with a rapid and severe surge in the number of cases but also limited availability of recommended medicines. Baricitinib has been known to reduce recovery time in COVID-19 pneumonia in association with remdesivir. Tofacitinib,...
Autores principales: | Singh, Pawan K, Lalwani, Lokesh K, Govindagoudar, Manjunath B, Aggarwal, Richa, Chaudhry, Dhruva, Kumar, Prashant, Gehlaut, Preeti |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Jaypee Brothers Medical Publishers
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645820/ https://www.ncbi.nlm.nih.gov/pubmed/34916741 http://dx.doi.org/10.5005/jp-journals-10071-23964 |
Ejemplares similares
-
The role of diaphragmatic thickness measurement in weaning prediction and its comparison with rapid shallow breathing index: a single-center experience
por: Lalwani, Lokesh Kumar, et al.
Publicado: (2022) -
COVID-19: Winter is COMING!
por: Chaudhry, Dhruva, et al.
Publicado: (2020) -
Role of Janus Kinase inhibitors in the management of pulmonary involvement due to Long COVID-19 disease: A case control study
por: Singh, Pawan Kumar, et al.
Publicado: (2023) -
Efficacy of different respiratory supports to prevent hypoxia during flexible bronchoscopy in patients of COPD: a triple-arm, randomised controlled trial
por: Sharma, Vinod Kumar, et al.
Publicado: (2023) -
Modified Barrier Enclosure for Noninvasive Respiratory Support in COVID-19 Outbreak
por: Kumar, Prashant, et al.
Publicado: (2020)